Gilead sciences to increase its ownership in arcus biosciences

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that gilead sciences is increasing its ownership in arcus to 19.5%, from approximately 13%, by purchasing 5,650,000 additional shares of arcus's common stock at a per share purchase price of $39.00. “gilead's additional investment in arcus demonstrates the strength of our relationship, a recognition of the depth of
RCUS Ratings Summary
RCUS Quant Ranking